// App-Quantinova.ai

P411 : Stable pharmacokinetics and biochemical markers of inflammatory bowel disease activity: Results from a real-world adalimumab biosimilar switching program

Researchers

Presenter

  • Moore, A.C

Principal Investigators

  • Russell, D

  • Dart, R

  • Dias, S

  • Ghuman, S

  • Petri, B

  • Sharma, E

  • Ray, S

  • Anderson, S

  • Mawdsley, J

  • Irving, P.M

  • Samaan, M.A

Medical Centers

  • IBD Centre- St Thomas’ Hospital- NHS Foundation Trust- Westminster Bridge Road- Guy’s and St Thomas’- London- SE EH- UK, Gastroenterology, London, United Kingdom

  • Peter Gorer Dept of Immunobiology- DIIID- King’s College London- nd Floor Borough Wing- Guy’s Hospital- Great Maze Pond- London- SE RT, Immunobiology, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

Biomarkers

  • C reactive protein

Drug/Treatment

  • Adalimumab biosimilar

  • Adalimumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Observational

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved